Head-To-Head Contrast: BioAtla (NASDAQ:BCAB) and Sorrento Therapeutics (OTCMKTS:SRNEQ)

Sorrento Therapeutics (OTCMKTS:SRNEQGet Free Report) and BioAtla (NASDAQ:BCABGet Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Institutional and Insider Ownership

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 71.7% of BioAtla shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 8.4% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Sorrento Therapeutics and BioAtla, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics 0 0 0 0 N/A
BioAtla 0 0 5 0 3.00

BioAtla has a consensus price target of $14.80, indicating a potential upside of 438.18%. Given BioAtla’s higher probable upside, analysts clearly believe BioAtla is more favorable than Sorrento Therapeutics.


This table compares Sorrento Therapeutics and BioAtla’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sorrento Therapeutics -852.82% N/A -106.85%
BioAtla N/A -89.27% -65.19%

Earnings and Valuation

This table compares Sorrento Therapeutics and BioAtla’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sorrento Therapeutics $62.84 million 0.22 -$572.84 million N/A N/A
BioAtla $250,000.00 527.34 -$106.48 million ($2.66) -1.03

BioAtla has lower revenue, but higher earnings than Sorrento Therapeutics.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.49, suggesting that its share price is 149% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.


BioAtla beats Sorrento Therapeutics on 8 of the 11 factors compared between the two stocks.

About Sorrento Therapeutics

(Get Free Report)

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

About BioAtla

(Get Free Report)

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.